INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,481,000 | -43.1% | 59,970 | -4.6% | 0.00% | -50.0% |
| Q3 2020 | $2,605,000 | -19.0% | 62,843 | -6.4% | 0.00% | -33.3% |
| Q2 2020 | $3,215,000 | -24.1% | 67,111 | -0.2% | 0.00% | -40.0% |
| Q1 2020 | $4,235,000 | -54.6% | 67,258 | -10.6% | 0.01% | -44.4% |
| Q4 2019 | $9,321,000 | +74.3% | 75,216 | -6.7% | 0.01% | +50.0% |
| Q3 2019 | $5,349,000 | -16.1% | 80,602 | +0.6% | 0.01% | -14.3% |
| Q2 2019 | $6,374,000 | -21.1% | 80,109 | +5.4% | 0.01% | +40.0% |
| Q1 2019 | $8,078,000 | +111.1% | 75,974 | +100.1% | 0.01% | 0.0% |
| Q4 2018 | $3,826,000 | -21.3% | 37,964 | -1.3% | 0.01% | -16.7% |
| Q3 2018 | $4,862,000 | +30.0% | 38,475 | -13.7% | 0.01% | +20.0% |
| Q2 2018 | $3,741,000 | +52.9% | 44,587 | +12.2% | 0.01% | +66.7% |
| Q1 2018 | $2,446,000 | +5.1% | 39,752 | -0.3% | 0.00% | 0.0% |
| Q4 2017 | $2,328,000 | +198.5% | 39,852 | +196.6% | 0.00% | +200.0% |
| Q3 2017 | $780,000 | – | 13,436 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WHITE SQUARE CAPITAL LLP | 65,500 | $7,117,000 | 11.05% |
| Ghost Tree Capital, LLC | 70,000 | $7,606,000 | 1.83% |
| Carmignac Gestion | 2,022,792 | $219,776,000 | 1.71% |
| Orbimed Advisors | 1,120,000 | $121,688,000 | 1.55% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 29,555 | $3,211,000 | 1.45% |
| Parametrica Management Ltd | 10,814 | $1,175,000 | 1.16% |
| BB BIOTECH AG | 255,719 | $27,784,000 | 1.03% |
| SECTORAL ASSET MANAGEMENT INC | 74,150 | $8,056,000 | 0.89% |
| ALTRINSIC GLOBAL ADVISORS LLC | 188,904 | $20,524,000 | 0.76% |
| FALCON POINT CAPITAL, LLC | 45,005 | $4,890,000 | 0.66% |